In a groundbreaking development, Adial Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ADIL ) has unveiled promising findings in the treatment of Alcohol Use Disorder (AUD) with its lead investigational drug, AD04 (low-dose ondansetron). A recently published peer-reviewed article showcases the remarkable clinical results, robust safety profile, and exceptional patient...
ADIAL saw an increase in volume and runup to 3.30 after which we saw a retrace to the 2.18 support level that held nicely. The upward trendline has been holding consistently on the daily and weekly charts. I am looking for a bullish engulfing or gap up opening with retrace to higher low to confirm the breakout continuation to test resistance at 2.82. If we can...
Its been consolidating for about a month and MACD is about to cross. Price broke thru the descending trend line. May see resistance at 1.97 on its way to 2.20
Pupm&Dump trading strategy idea.
$ADIL is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $2,10;
stop-loss — $2,35.
take-profit — $1,85.
Do not view this idea as a recommendation for trading or...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, I am keeping a close watch on ADIL. It seems to have continued bullish support and looks like it can continue on a positive run all the until way next week for a sell target of $1.75 w/ decent profit turnover.
As Adial Pharmaceuticals advances its Phase 3 clinical trial of AD04 for the treatment of alcohol use, insiders are showing confidence in the company. Today they appointed Mark Howard Peikin as chief strategy officer, and he took the position without a salary. Instead, he accepted a stock option as his sole compensation plan. Chief medical officer Johnson A....
10:09 AM EDT, 09/11/2019 (MT Newswires) -- Adial Pharmaceuticals (ADIL) said Wednesday that it has successfully retested a previously manufactured supply of clinical trial packaged tablets of the investigational drug AD04 for the treatment of alcohol use disorder.
The company said tests showed that the clinical trial materials passed reevaluation and are eligible...
ADIL has less of the pattern to follow the historicals but as far as it's in the wedge pattern, this is a good time to add to the dips. I've been watching the channel and trading it but hard for me to gauge a breakout. Any news could be the catalyst and we could see a good July.
Adial Pharmaceuticals, Inc. today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3...
